News Author: Jeff Evans Publish date: April 17, 2018
A phase 3b trial shows the investigational monoclonal antibody was effective out to 3 months so far.
News Author: Jeff Evans Publish date: April 17, 2018
Top picks include presentations on SMA, targeting and screening for tau in Alzheimer’s, and the BigBrain High Resolution 3D Digital Human Brain Atl...
News Author: Jeff Evans Publish date: February 20, 2018
Pilot studies examine two different technologies to treat freezing of gait and other aspects of gait dysfunction in Parkinson’s disease patients.
News Author: Jeff Evans Publish date: February 14, 2018
DAS28 and HAQ scores improved in patients with early RA in daily clinical practice.
News Author: Jeff Evans Publish date: November 20, 2017
SAN DIEGO – The RA APM helps to reduce barriers to good care by providing adequate reimbursement for cognitive services through monthly payments ra...
News Author: Jeff Evans Publish date: November 8, 2017
SAN DIEGO – An analysis’ findings “[support] a role for additional factors in the pathogenesis of gout,” according to Nicola Dalbeth, MD.
News Author: Jeff Evans Publish date: November 7, 2017
The American College of Rheumatology’s advocacy website shows members how to help.
News Author: Jeff Evans Publish date: October 31, 2017
Studies include phase 3 results for upadacitinib, phase 1/2 results of the monoclonal antibody E6011, and phase 2 safety results for filgotinib.
News Author: Jeff Evans Publish date: October 28, 2017
A 2-day premeeting course and dedicated session during the meeting will highlight some of the latest developments in precision medicine for rheumat...
News Author: Jeff Evans Publish date: October 27, 2017
Two debates at this year’s meeting are set to offer interesting viewpoints on two unsettled issues.
News Author: Jeff Evans Publish date: October 26, 2017
A preponderance of evidence suggests how difficult it is for PsA patients with low disease activity to discontinue the drugs.
News Author: Jeff Evans Publish date: October 12, 2017
The study accounted for many confounding factors to determine the driving force behind elevated mortality in lupus patients who are poor.
News Author: Jeff Evans Publish date: October 6, 2017
Six plenary sessions over 3 days will cover neuronal circuits and behavior, global neurology, precision medicine, antisense oligonucleotide therapi...
News Author: Jeff Evans Publish date: October 5, 2017
A panel of experts will describe the latest ideas and efforts to develop tools to understand multiple levels of neural circuitry and brain function...
News Author: Jeff Evans Publish date: October 5, 2017
Morning sessions during Oct. 15-17 offer something for everyone for career development.
